Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results and highlights for the first quarter ended March 31, 2008.

"We made significant progress in both of our development programs during the first quarter," said Steve Worland, Ph.D., President and CEO of Anadys. "We successfully completed preclinical evaluation of ANA598, our non-nucleoside polymerase inhibitor for the treatment of hepatitis C, and have subsequently filed an IND for this product candidate. We also commenced dosing with ANA773, our oral TLR7 agonist prodrug, in patients with advanced cancer." Providing an updated cash outlook for 2008, Dr. Worland added, "Based on promising results from the preclinical evaluation of ANA598, we have made the strategic decision to accelerate certain non-clinical development activities for ANA598 into 2008 and now expect our cash utilization this year to be in the range of $29 million to $31 million."

Financial Results

As of March 31, 2008, the Company's cash, cash equivalents and securities available-for-sale totaled $48.8 million compared to $56.5 million as of December 31, 2007.

During the first quarter of 2008 the Company had no revenue, compared to $1.1 million in revenue for the same quarter of 2007. The revenue in the first quarter of 2007 was primarily derived from the amortization of an upfront payment and milestone payment under a prior collaboration.

Research and development expenses were $6.0 million for the first quarter of 2008 compared to $6.7 million for the first quarter of 2007. The $0
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
5. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
6. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
9. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
11. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. ... company focused on the development and commercialization of a ... and cholesterol gallstones, today announced financial results for the ... 2014 Financial Summary: , Reported cash and cash ... with $137,000 at December 31, 2013.  , Reported ...
(Date:7/25/2014)... 25, 2014 At the request of ... a 60-day extension for the public comment period (Docket ... for Model Aircraft established by Congress as part of ... 60-day extension establishes the new deadline for comments as ... of Transportation/FAA notice published in the Federal Register on ...
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... Md., March 27 Local biotechnology leader,MedImmune ... student Yiwei Li,has received the distinguished "MedImmune ... ScienceMONTGOMERY project. The company sponsored the,Montgomery County ... year and presented the award to recognize ...
... - IntelliPharmaCeutics Ltd. (Delaware),is pleased to announce ... trial for its new abuse-resistant, alcohol-resistant once-a-day,oral ... of Toronto ("IntelliPharmaCeutics" or the "Company"). The ... its novel ReXista(TM) abuse and,alcohol resistant drug ...
... (Nasdaq: PRXL ) today announced that it ... pharmacology business of,Synchron Research in Ahmedabad, India. The ... in Poitiers, France to a subsidiary of,Synchron, SYNEXEL ... new agreement, PAREXEL,s ownership interest in,the Ahmedabad Phase ...
Cached Biology Technology:Seneca Valley High School Student Receives Science Award From MedImmune 2Seneca Valley High School Student Receives Science Award From MedImmune 3IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 2IntelliPharmaCeutics Announces Successful Completion of a Pilot Clinical Trial for its Abuse and Alcohol Resistant Sustained Release Oxycodone 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 2PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 3PAREXEL International Expands Relationship with Synchron Research in India and Divests Bioanalytical Laboratory in France 4
(Date:7/25/2014)... this summer and some of the smoke from those fires ... collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the ... has descended over the Great Lakes region of the United ... from July 23, 2014 (first image feature highlighted below) clearly ... southeastward. In the image, it is over Manitoba and ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... girls reach puberty is influenced by ,imprinted genes,a subset of ... gene. This is the first evidence that imprinted genes ... of this study were published today in the journal ... menarche, is a marker for the timing of puberty in ... varies between girls, is an inherited trait, and is linked ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2Could age of first period influence development of diseases in older women? 2
... Four new reservoirs linked to rice cultivation built in the ... the 1990,s have allowed various migratory dabbling duck species to ... University of Extremadura propose that Vegas Altas del Guadiana is ... Many aquatic migratory bird populations are in decline and the ...
... even the most intelligent, complex brains can be taken by a ... it was false. When the brain fires up the network ... used for analysis, a pivotal study led by a Case Western ... blind to the public relations fiasco his cost-cutting decision has made? ...
... has given new clues as to how some E. coli ... slightly different transmission strategies, with some being better adapted to live ... of food poisoning due to contamination of vegetables by dangerous strains ... making sure our food remains safe., E. coli is most ...
Cached Biology News:Ducks flock to Extremadura thanks to its ricefields 2Ducks flock to Extremadura thanks to its ricefields 3Empathy represses analytic thought, and vice versa 2Empathy represses analytic thought, and vice versa 3Empathy represses analytic thought, and vice versa 4Empathy represses analytic thought, and vice versa 5E. coli adapts to colonize plants 2
RNA oligomers from 10 to 50 bases purified by PAGE and MS-checked. RNAs are supplied dried and fully deprotected....
... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... is available as a one-cabinet ...
... Anti-Reverse Cap Analog (ARCA) is a ... OH group (closer to m7G) is replaced ... RNA polymerase can only initiate transcription with ... incorporation in the forward orientation. As a ...
...
Biology Products: